Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Kneat will release its financial results for the quarter ended March 31, 2026, after TSX market close on May 13, 2026.
-
Abivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical...
-
Le recrutement d’un Directeur Financier, d’une Directrice Juridique et d’une Directrice des Ressources Humaines reflète le renforcement de l’organisation d’Inventiva à mesure que la société se prépare...
-
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva’s organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes...
-
Positive results from “LAPNET-01,” phase 1b trial of NP137 in patients with pancreatic ductal adenocarcinoma, published in Nature.
-
CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6,...
-
CEO Gareth Sheridan appears as guest on the Jack Neel Podcast
-
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to Plan Oral Minisymposium Presentation Demonstrates That EVOLVE T Cell Engagers Drive Greater T Cell Activation, Proliferation and...
-
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in...
-
PharmAla files Q2 quarterly financials with increased customer deposits.